Jarrell Imamura
YOU?
Author Swipe
View article: Remarkable response to anti-PD-L1 blockade in relapsed and refractory metastatic malignant giant cell tumor of bone: a case report
Remarkable response to anti-PD-L1 blockade in relapsed and refractory metastatic malignant giant cell tumor of bone: a case report Open
PD-L1 blockade should be considered for MGCTB expressing PD-L1. Unfortunately, pembrolizumab was stopped, which likely allowed for tumor progression in this case.
View article: Immunotherapy in the Treatment of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma
Immunotherapy in the Treatment of Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma Open
Opinion Statement Undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) are among the most common adult soft tissue sarcoma (STS) subtypes. Due to their high genetic complexity, heterogeneity, and lack of specific genetic a…
View article: Transcriptomic Profiling of Relapsed Rhabdomyosarcoma: Pre‐ and Post‐Treatment Tissue Analysis Reveals Molecular Characteristics of Treatment Failure
Transcriptomic Profiling of Relapsed Rhabdomyosarcoma: Pre‐ and Post‐Treatment Tissue Analysis Reveals Molecular Characteristics of Treatment Failure Open
Background Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Historically classified based on histology, advances in molecular profiling have allowed further sub‐classification, which has improved risk stratificat…
View article: A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC)
A NOVEL ORTHOTOPIC MURINE MODEL OF NEUROENDOCRINE BLADDER CANCER: INSIGHTS INTO THE MOLECULAR DRIVERS OF SMALL CELL BLADDER CANCER (SCBC) Open
SCBC is an aggressive subtype of bladder cancer with high metastatic potential and few effective therapies. The defining mutations of neuroendocrine cancers include loss-of-function mutations in p53 and Rb and gain-of-function mutations in…
View article: Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer
Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer Open
Half of all men with advanced prostate cancer (PCa) inherit at least 1 copy of an adrenal-permissive HSD3B1 (1245C) allele, which increases levels of 3β-hydroxysteroid dehydrogenase 1 (3βHSD1) and promotes intracellular androgen biosynthes…
View article: Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution
Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution Open
Androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, and the development of castrate-resistant prostate cancer (CRPC) is the primary cause of prostate cancer-related mortality. While CRPC typically devel…